BRAIN CANCER

HER2 Breast Cancer

BREAST CANCER

Bladder Cancer

Prostate Cancer

Renal Cell Carcinoma

GENITOURINARY CANCERS

Liquid Biopsies

GENOMIC TESTING

Colorectal Cancer

GIST

Gastric Cancer

GI CANCERS

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

GYNECOLOGIC CANCERS

HEAD & NECK CANCERS

Bone Marrow & Stem Cell Transplant

HEMATOLOGY

CAR T-Cell Therapy

IMMUNOTHERAPY

Chronic Lymphocytic Leukemia

Chronic Myeloid Leukemia

LEUKEMIAS

Biomarker-Driven Lung Cancer

EGFR+ Lung Cancer

MET-Targeted Therapy

Small Cell Lung Cancer

LUNG CANCER

DLBCL

Follicular Lymphoma

Mantle Cell Lymphoma

LYMPHOMAS

MPNs

MULTIPLE MYELOMA

NTRK GENE FUSIONS

SARCOMA

Melanoma

SKIN CANCERS

THYROID CANCERS

NEWS

All News

FDA Briefs

Oncology Icons

Special Reports

Voices from the Field

CONFERENCES

Conference Coverage

Conference Listing

Data Dialogue with the Oncology Brothers

MEDIA

All Videos

Case-Based Peer Perspectives

Expert Perspective Virtual Tumor Board

Interviews

Investigator Perspectives

Medical World News

Pivotal Practice Views with the Oncology Brothers

Podcasts

Precision Medicine

Speaking Out

PUBLICATIONS

All Publications

Evolving Paradigms

Peers & Perspectives in Oncology

Targeted Therapies in Oncology

CASE-BASED ROUNDTABLE

PARTNERS

RESOURCES

CME/CE

Clinical Trials

Precision Medicine Perspectives

Press Releases

Treatment Resources

SUBSCRIBE

Targeted Oncology provides news, videos, and reviews on the rapidly evolving world of targeted therapies and immunotherapy for oncologists treating patients in a community setting.

About Us

Advertise

Contact Us

CureToday.com

CancerNetwork.com

OncLive.com

OncNursingNews.com

Do Not Sell My Information

Privacy

Terms & Conditions

Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

Facebook

Linkedin

Twitter

YouTube

Instagram

Featured Clinical Focus

BTK Inhibitors: In-Focus

Bone Marrow & SCT

EGFR-Positive Lung Cancer

Lung Cancer

Multiple Myeloma

Thyroid Cancers

Clinical Focus

Brain Cancer

Breast Cancer

Gastrointestinal Cancer

Genitourinary Cancers

Gynecologic Cancers

Head & Neck Cancers

Hematology

Leukemias

Lymphomas

Sarcoma

Skin Cancers

Spotlight

This roundtable series looks at combination treatments in the unresectable or metastatic bladder cancer population, as discussed by key opinion leaders at virtual live events and interviews.

Patients With Advanced Bladder Cancer Given Combination Therapies

Matthew Galsky, MD, discusses the disease-free survival of nivolumab vs placebo in patients with high-risk muscle-invasive bladder cancer.

Nivolumab Shows Improved DFS in ITT and PD-L1–High Bladder Cancer

Matthew Galsky, MD, professor of medicine (hematology and medical oncology), director of genitourinary medical oncology, codirector of the Center of Excellence for Bladder Cancer, and associate director for Translational Research at The Tisch Cancer Institute at Mount Sinai in New York, discusses the efficacy of adjuvant nivolumab (Opdivo) in the phase 3 CheckMate 274 trial (NCT02632409).

Results from the randomized, double-blind, multicenter CheckMate 274 study were initially published in 

 looking at disease-free survival (DFS) in all patients and patients with PD-L1 expression of 1% or higher as the primary end points. Investigators demonstrated that patients with high-risk muscle-invasive bladder cancer experienced longer DFS with adjuvant nivolumab compared with placebo after radical surgery. This was seen in the intention-to-treat (ITT) population and those with positive PD-L1 expression, according to Galsky.

Nivolumab continued to show benefit over placebo for patients’ DFS, non–urothelial tract recurrence-free survival, and distant metastasis-free survival in the extended follow-up of these data. Results for CheckMate 274 were updated at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

 In the initial report of CheckMate 274 where the coprimary end points were reported, the median follow-up was about 5.9 months and DFS in the all-comer population was significantly improved with adjuvant nivolumab vs placebo, with an HR of 0.7. In the patients with tumors with high levels of PD-L1 expression, the effect size was a bit larger, and the HR for DFS was 0.55.

 This study has now been analyzed with longer-term follow-up, so now there's a median follow-up of about 3 years, and the effect size in both the ITT population and in patients with tumors with high PD-L1 expression is virtually identical to what it was with the initial report of the data. 